Anxiety News and Research

Latest Anxiety News and Research

Patients can reduce their health care costs, improve overall wellness by communicating with doctors

Patients can reduce their health care costs and improve their overall wellness by communicating more effectively with their doctors, according to a recent report and list of 10 tips released by InfoMedics, Inc., a patient feedback company that works to improve patient-physician communication.

11 Dec 2009

Psychologists can help people deal with anxiety and depression symptoms more effectively

From Thanksgiving to New Year's, there are many wishes for everyone to have a blissful and celebratory holiday season. But for many people, the holidays bring more misery than mirth, particularly at a time when the ailing economy can't seem to recover quickly enough and money worries remain on people's minds.

10 Dec 2009

Computer-based intervention reduces anxiety and depression among people with facial disfigurement

Using Face IT - a new computer-based teaching aid that includes interactive videos - can reduce anxiety, depression and appearance concerns among people with facial disfigurement.

10 Dec 2009

Bill Protzmann to present on the healing power of music to The 60 Minute University

Bill Protzmann brings his presentation on the healing power of music to The 60 Minute University in Indian Wells on Monday December 14th, 2009 from 9-10am, at the Miramonte Resort & Spa.

10 Dec 2009

Social scientists say compassion is humans' strongest trait

Researchers at UC Berkeley are challenging long-held beliefs that human beings are wired to be selfish. In a wide range of studies, social scientists are amassing a growing body of evidence to show we are evolving to become more compassionate and collaborative in our quest to survive and thrive.

10 Dec 2009

Results from Tulip PETAL Study of elagolix announced by Neurocrine Biosciences

Neurocrine Biosciences, Inc. today announced top-line efficacy and safety results from the Tulip PETAL Study (703 Study), its fifth Phase 2 clinical trial using its proprietary, orally-active nonpeptide Gonadotropin-Releasing Hormone (GnRH) receptor antagonist, elagolix, in patients with endometriosis.

10 Dec 2009

VERTICAL Phase II trial results for NHL released

The Takeda Oncology Company today reported data from a clinical trial evaluating a VELCADE based combination for patients with relapsed/refractory non-Hodgkin’s lymphoma (NHL).

9 Dec 2009

Risk of serious injury at summer camps is low compared to other popular youth activities

Although a trip to summer camp is highly anticipated by over 11 million children and adults each year, sending a child off to summer camp can be a source of anxiety for parents. Findings from a new study published in the December issue of Injury Prevention should ease their concerns however.

9 Dec 2009

Experts call on Europe's policy makers to take urgent action against preventable strokes

A report launched today by experts from medical and patient communities calls on Europe's policy makers to take urgent action against preventable strokes that strike thousands of atrial fibrillation (AF) patients each year

9 Dec 2009

Smokers taking the Respiragene test try to quit smoking, reveals study

Smokers who see their own personal risk of developing lung cancer after genetic-based testing show stronger intention and take more action on quitting smoking, according to clinical trial results presented to an American Association of Cancer Research conference.

9 Dec 2009

NeuroPace announces clinical trial results demonstrating the RNS System

NeuroPace, Inc. today announced that results from its pivotal trial demonstrated the RNS- System, a novel investigational device that utilizes responsive brain neurostimulation, significantly reduced the frequency of seizures among people who have a common form of epilepsy that is difficult to treat with medication.

9 Dec 2009

TMZ and small molecule combination appears to lower tumor resistance

University of Florida researchers have found a way to use just a fraction of the normal dosage of a highly toxic, debilitating chemotherapy drug to achieve even better results against colon cancer cells.

9 Dec 2009

The National Fragile X Foundation awards $100,000 grant for study of minocycline in FXS children

The National Fragile X Foundation has awarded a translational research seed grant of $100,000 to Dr. Randi J. Hagerman at the UC Davis M.I.N.D. Institute in California for a study of minocycline in the treatment of children with fragile X syndrome (FXS). Hagerman is an internationally recognized clinician and clinical researcher on FXS, the most common cause of inherited mental impairment.

8 Dec 2009

Veran Medical Technologies' SPiN Drive System receives FDA marketing clearance

Veran Medical Technologies announced today that it received clearance (K091934) from the U.S. Food and Drug Administration (FDA) to market a product for the delivery of instruments through the pulmonary tract. "Veran is excited about this clearance as it allows the company to address a huge unmet clinical need in lung cancer diagnosis and treatment," said Jerome R. Edwards, Veran president and chief executive officer.

8 Dec 2009

Clinical trial results of VELCADE based combinations for MM to be presented at the ASH meeting

Millennium: The Takeda Oncology Company today reported the presentation of results from a double randomized Phase III clinical trial of VELCADE based combinations for the treatment of patients with previously untreated multiple myeloma (MM). The VELCADE based combinations evaluated in the study demonstrated two-year overall survival rates ranging between 81 and 88 percent.

8 Dec 2009

CeNeRx BioPharma's TriRima reversibly inhibits MAO-A, confirms PET imaging study

CeNeRx BioPharma, Inc., a clinical stage company developing innovative treatments for diseases of the central nervous system, today announced that a newly published PET imaging study in human subjects confirms that CeNeRx's novel compound TriRima(TM) reversibly inhibits MAO-A (monoamine oxidase A), an enzyme in the brain that plays a key role in the regulation of mood.

8 Dec 2009

NeuroPace's RNS System effective for controlling seizures not treatable by medication in epilepsy patients

NeuroPace, Inc. today announced that results from its pivotal trial demonstrated the RNS® System, a novel investigational device that utilizes responsive brain neurostimulation, significantly reduced the frequency of seizures among people who have a common form of epilepsy that is difficult to treat with medication.

8 Dec 2009

New NNNS screening tool developed to identify newborn at risk

When a baby is born, new parents often wonder, "Will he be the next President of the United States?" or "Could she be the one to find a cure for cancer?" But the underlying question for many specialists is, "Is this child 'at risk' for developmental issues?"

8 Dec 2009

Young adults with higher blood lead levels more likely to have panic disorders, reveals research

Young adults with higher blood lead levels appear more likely to have major depression and panic disorders, even if they have exposure to lead levels generally considered safe, according to a report in the December issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

8 Dec 2009

CAM314 randomized Phase 3 clinical trial results released

Genzyme Corporation announced data from its CAM314 randomized Phase 3 clinical trial comparing Campath (alemtuzumab) in combination with Fludara (fludarabine phosphate) (FluCAM) to Fludara alone in patients with relapsed and refractory chronic lymphocytic leukemia (CLL) demonstrated that the FluCAM regimen significantly reduced the risk of disease progression or death compared to single-agent Fludara.

8 Dec 2009

Anxiety News and Research

Latest Anxiety News and Research

Patients can reduce their health care costs, improve overall wellness by communicating with doctors

Psychologists can help people deal with anxiety and depression symptoms more effectively

Computer-based intervention reduces anxiety and depression among people with facial disfigurement

Bill Protzmann to present on the healing power of music to The 60 Minute University

Social scientists say compassion is humans' strongest trait

Results from Tulip PETAL Study of elagolix announced by Neurocrine Biosciences

VERTICAL Phase II trial results for NHL released

Risk of serious injury at summer camps is low compared to other popular youth activities

Experts call on Europe's policy makers to take urgent action against preventable strokes

Smokers taking the Respiragene test try to quit smoking, reveals study

NeuroPace announces clinical trial results demonstrating the RNS System

TMZ and small molecule combination appears to lower tumor resistance

The National Fragile X Foundation awards $100,000 grant for study of minocycline in FXS children

Veran Medical Technologies' SPiN Drive System receives FDA marketing clearance

Clinical trial results of VELCADE based combinations for MM to be presented at the ASH meeting

CeNeRx BioPharma's TriRima reversibly inhibits MAO-A, confirms PET imaging study

NeuroPace's RNS System effective for controlling seizures not treatable by medication in epilepsy patients

New NNNS screening tool developed to identify newborn at risk

Young adults with higher blood lead levels more likely to have panic disorders, reveals research

CAM314 randomized Phase 3 clinical trial results released

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Anxiety News and Research

Latest Anxiety News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in